Amolyt Pharma SAS announced that it has received €67.6 million in an equity round of funding co-led by new investors, Sectoral Asset Management Inc and Andera Partners on September 16, 2021. The transaction also includes participation from new investor, ATEM Capital and returning investors, Life Sciences Partners BV, Novo Holdings A/S, Kurma Partners SA, InnoBio 2, FCPI, Bpifrance Investissement SAS, OrbiMed Advisors LLC, Pontifax Ltd., Turenne Santé, Credit Agricole Creation, Crédit Agricole Régions Investissement SAS, Eurazeo SE and Partners Innovation Management Co., LLC.